Luciana Molinero to Treatment Outcome
This is a "connection" page, showing publications Luciana Molinero has written about Treatment Outcome.
Connection Strength
0.175
-
Tumor immune microenvironment and genomic evolution in a patient with metastatic triple negative breast cancer and a complete response to atezolizumab. J Immunother Cancer. 2019 10 23; 7(1):274.
Score: 0.070
-
Automated tumor immunophenotyping predicts clinical benefit from anti-PD-L1 immunotherapy. J Pathol. 2024 06; 263(2):190-202.
Score: 0.024
-
Molecular determinants of response to PD-L1 blockade across tumor types. Nat Commun. 2021 06 25; 12(1):3969.
Score: 0.020
-
A PK/PD Analysis of Circulating Biomarkers and Their Relationship to Tumor Response in Atezolizumab-Treated non-small Cell Lung Cancer Patients. Clin Pharmacol Ther. 2019 02; 105(2):486-495.
Score: 0.016
-
Clinical activity and safety of atezolizumab in patients with recurrent glioblastoma. J Neurooncol. 2018 Nov; 140(2):317-328.
Score: 0.016
-
Gene Expression Profiling in BRAF-Mutated Melanoma Reveals Patient Subgroups with Poor Outcomes to Vemurafenib That May Be Overcome by Cobimetinib Plus Vemurafenib. Clin Cancer Res. 2017 Sep 01; 23(17):5238-5245.
Score: 0.015
-
The composition of the microbiota modulates allograft rejection. J Clin Invest. 2016 07 01; 126(7):2736-44.
Score: 0.014